These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 2502552)
1. Altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries. Le Dafniet M; Blumberg-Tick J; Gozlan H; Barret A; Joubert Bression D; Peillon F J Clin Endocrinol Metab; 1989 Aug; 69(2):267-71. PubMed ID: 2502552 [TBL] [Abstract][Full Text] [Related]
2. Normal and adenomatous human pituitaries secrete thyrotropin-releasing hormone in vitro: modulation by dopamine, haloperidol, and somatostatin. Le Dafniet M; Lefebvre P; Barret A; Mechain C; Feinstein MC; Brandi AM; Peillon F J Clin Endocrinol Metab; 1990 Aug; 71(2):480-6. PubMed ID: 1974264 [TBL] [Abstract][Full Text] [Related]
3. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas. Chang CC; Chen FW; Hsieh HC Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734 [TBL] [Abstract][Full Text] [Related]
4. Evidence of thyrotropin-releasing hormone (TRH) and TRH-binding sites in human nonsecreting pituitary adenomas. Le Dafniet M; Grouselle D; Li JY; Kujas M; Bression D; Barret A; Tixier-Vidal A; Peillon F J Clin Endocrinol Metab; 1987 Nov; 65(5):1014-9. PubMed ID: 3117830 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206 [TBL] [Abstract][Full Text] [Related]
6. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Serri O; Marchisio AM; Collu R; Hardy J; Somma M Horm Res; 1984; 19(2):97-102. PubMed ID: 6706294 [TBL] [Abstract][Full Text] [Related]
7. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture. Ishibashi M; Yamaji T J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494 [TBL] [Abstract][Full Text] [Related]
8. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas. Kim K; Arai K; Sanno N; Teramoto A; Shibasaki T Clin Endocrinol (Oxf); 2001 Mar; 54(3):309-16. PubMed ID: 11298082 [TBL] [Abstract][Full Text] [Related]
9. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. Ishibashi M; Yamaji T J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors in immunohistochemically characterized null cell adenomas and normal human pituitaries. Lloyd RV; Anagnostou D; Chandler WF Mod Pathol; 1988 Jan; 1(1):51-6. PubMed ID: 2467283 [TBL] [Abstract][Full Text] [Related]
11. Effects of thyrotropin-releasing hormone and gonadotropin-releasing hormone on inositol phospholipid turnover in endocrinologically inactive pituitary adenomas and prolactinomas. Levy A; Lightman SL J Clin Endocrinol Metab; 1989 Jul; 69(1):122-6. PubMed ID: 2543687 [TBL] [Abstract][Full Text] [Related]
12. [Neurohormones coming from the normal and tumoral human anterior pituitary. Secretion and regulation in vitro]. Peillon F; Le Dafniet M; Garnier P; Feinstein MC; Donnadieu M; Barret A; Gautron JP; Brandi AM; Benlot C; Lagoguey A Pathol Biol (Paris); 1989 Sep; 37(7):840-5. PubMed ID: 2576565 [TBL] [Abstract][Full Text] [Related]
13. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297 [TBL] [Abstract][Full Text] [Related]
14. Pituitary adenomas in acromegalic patients: an immunohistochemical and endocrinological study with special reference to prolactin-secreting adenoma. Kanie N; Kageyama N; Kuwayama A; Nakane T; Watanabe M; Kawaoi A J Clin Endocrinol Metab; 1983 Dec; 57(6):1093-101. PubMed ID: 6415083 [TBL] [Abstract][Full Text] [Related]
15. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350 [TBL] [Abstract][Full Text] [Related]
16. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675 [TBL] [Abstract][Full Text] [Related]
18. Evidence of abnormal dopaminergic control of prolactin in patients with hypothalamic and pituitary tumors. Cabranes JA; Almoguera I; del Olmo J; Prensa A; Pablos I; Charro AL J Med; 1986; 17(1):25-39. PubMed ID: 3035040 [TBL] [Abstract][Full Text] [Related]
19. Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone. Joubert D; Benlot C; Lagoguey A; Garnier P; Brandi AM; Gautron JP; Legrand JC; Peillon F J Clin Endocrinol Metab; 1989 Mar; 68(3):572-7. PubMed ID: 2493037 [TBL] [Abstract][Full Text] [Related]
20. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]